Furlong, C.E., Cole, T.B., Jarvik, G.P., Costa, L.G., Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics, 2002, Vol. 3(3), pp. 341-348.
Hassett, C., Richter, R.J., Humbert, R., Chapline, C., Crabb, J.W., Omiecinski, C.J., et al. Characterization of Cdna Clones Encoding Rabbit and Human Serum Paraoxonase - the Mature Protein Retains Its Signal Sequence. Biochem, 1991, Vol. 30(42), pp. 10141-10149.
Mackness, M.I., Esterases: Enzymes looking for a role?. Biochem Pharmacol, 1989, Vol. 38(3), pp. 385-390.
Aviram, M., Rosenblat, M., Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radical Bio Med, 2004, Vol. 37(9), pp. 1304-1316.
Furlong, C.E., Richter, R.J., Chapline, C., Crabb, J.W., Purification of Rabbit and Human Serum Paraoxonase. Biochem, 1991, Vol. 30(42), pp. 10133-10140.
Costa, L.G., Cole, T.B., Jarvik, G.P., Furlong, C.E., Functional genomics of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annual Review of Medicine-Selected Topics in the Clinical Sciences, 2003, Vol. 54, pp. 371-392.
Billeclke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., La, B.N., Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos, 2000, Vol. 28(11), pp. 1335-1342.
jakubowski, H., Calcium-dependent human serum homocysteinethiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem, 2000, Vol. 275, pp. 3962-3975.
Himbergen, T.M., Roest, M., Graaf, J., Jansen, E.H.J.M., Hattori, H., Kastelein, J.J.P., et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res, 2005, Vol. 46(3), pp. 445-451.
Obata, T., Ito, T., Yonemura, A., Ayaori, M., Nakamura, H.F.O., R192Q paraoxonase gene variant is associated with a change in HDL-cholesterol level during dietary caloric restriction in nondiabetic healthy males. J Atheroscler Thromb, 2003, Vol. 10, pp. 57-62.
Voetsch, B., Benke, K.S., Damasceno, B.P., Siqueira, L.H., Loscalzo, J., Paraoxonase 192 Gln-Arg polymorphism - An independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke, 2002, Vol. 33(6), pp. 1459-1464.
Schmidt, R., Schmidt, H., Fazekas, F., Kapeller, P., Roob, G., Lechner, A., et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms - Three-year follow-up of the Austrian stroke prevention study. Arterioscler Thromb Vasc Biol, 2000, Vol. 20(7), pp. 1811-1816.
Mackness, B., Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet, 1999, Vol. 6, pp. 468-469.
Leviev, I., Negro, F., James, R.W., Two alleles of the human paraoxonase gene produce different amounts of mRNA - An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol, 1997, Vol. 17(11), pp. 2935-2939.
Blatter-Garin, M.C., James, R.W., Dussoix, P., Blanche, H., Passa, P., Froguel, P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of theenzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular diseasein diabetes. J Clin Invest. 1997, Vol. 99, pp. 62-66.
Leviev, I., James, R.W., Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol, 2000, Vol. 20(2). Pp. 516-521.
Durrington, P.N., Mackness, B., Mackness, M.I., Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol, 2001, Vol. 21(4), pp. 473-480.
Ng, C.J., Shih, D.M., Hama, S.Y., Villa, N., Navab, M., Reddy, S.T., The paraoxonase gene family and atherosclerosis. Free Radical Biology and Medicine, 2005, Vol. 15; 38(2), pp. 153-163.
Bartlett, J.M.S., Stirling, D., PCR protocols: Humana Press; 2003.
Humbert, R., Adler, D.A., Disteche, C.M., Hassett, C., Omiecinski, C.J., Furlong, C.E., The Molecular-Basis of the Human Serum Paraoxonase Activity Polymorphism. Nat Genet, 1993, Vol. 3(1), pp. 73-76.
Adkins, S., Gan, K.N., Mody, M., La, D.B.N., Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Gln or Arg at position 192, for the respective A or B allozymes. Am J Hum Genet, 1991, Vol. 40, pp. 277-282.
Sepahvand, F., Rahimi-Moghaddam, P., Shafiei, M., Ghaffari S.M., Rostam-Shirazi, M., Mahmoudian, M., Frequency of Paraoxonase 192/55 Polymorphism in an Iranian Population. J Tox Env Health, Part A., 2007, Vol. 70(13), pp. 1125-1129.
Wang, X., Fan, Z., Huang, J., Su, S., Yu, Q., Zhao, J., et al. Extensive Association Analysis Between Polymorphisms of PON Gene Cluster With Coronary Heart Disease in Chinese Han Population. Arterioscler Thromb Vasc Biol, 2003, Vol. 23(2), pp. 328-334.
Suehiro, T., Nakamura, T., Inoue, M., Shiinoki, T., Ikeda, Y., Kumon, Y., et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis, 2000, Vol, 150(2), PP. 295-298.
Sardo, M.A, Campo, S., Bonaiuto, M., Bonaiuto, A., Saitta, C., Trimarchi, G., et al. Antioxidant effect of atorvastatin is independent of PON1 gene T(–107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin, 2005, Vol. 21(5), pp. 777-784.
Parra, S., Alonso-Villaverde. C., Coll, B., Marsillach, J., Aragon, G., et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis, 2007, Vol. 194(1), pp. 175-181.
Clarimon, J., Eerola, J., Hellstrom, I., Tienari, P.J., Singleton., A., Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. Neurosci Lett, 2004, Vol. 367(2), pp. 168-170.
Gaidukov, L., Rosenblat, M., Aviram, M., Tawfik, D.S., The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res, 2006, Vol. 47(11), pp. 2492-2502.